CSL's break-through haemophilia drugs could be on the market within one to two years after trial data showed the drugs are an effective, safe, and less burdensome way to treat the blood clotting disorder.

The $42 billion blood products and vaccines maker is now in the home stretch of a decade-long journey that could deliver the group hundreds of millions in sales and transform the lives of haemophilia sufferers.

"This is a culmination of 10 years of work, a lot of money, and our peoples' time and effort," CSL chief scientific officer Andrew Cuthbertson told Fairfax Media from Toronto, Canada.

"After years of hard slog we can see the finish line."

Dr Cuthbertson is in Canada presenting data from clinical trials to a meeting of more than 10,000 medical professionals from over 100 countries.

The trials showed that CSL's recombinant coagulation factor IX, used to treat haemophilia B, and its single chain recombinant factor VIII, used to threat haemophilia A, safely prevent bleeding.

Current treatments require patients to go to hospital for injections three times a week, but CSL's drugs demonstrated efficacy with just one dose every one to two weeks.

"It's a big difference and that's why we're so excited about bringing this treatment to patients," Dr Cuthbertson said.

"We are on track to put the data regulatory agencies around the world...we are under intense scrutiny but we think the data are strong."

For more details, go to: http://www.smh.com.au/business/markets/csl-haemophilia-drug-closer-to-market-after-positive-trials-20150625-ghw9wn